by: Parent Project Muscular DystrophyNS Pharma’s Exon 53 Skipping Program (November 2016)
On November 16, 2016, Parent Project Muscular Dystrophy and NS Pharma (US subsidiary of Nippon Shinyaku, Co.,Ltd) hosted a webinar to discuss NS Pharma’s Exon 53 Skipping Program. Dr. Clemens and Lauren Morgenroth reviewed data from the Phase I study conducted in Japan and presented the study design for the trial that is opening in the US later this month.
